Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure

NCT00063687 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00063687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00063687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure
Lead sponsor
Advanz Pharma
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2003
Completion date
June 30, 2005
Enrollment
400
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure